Catalog No.S1354 Synonyms: A-65006, AG-1749
Molecular Weight(MW): 369.36
Lansoprazole is a proton-pump inhibitor (PPI) which prevents the stomach from producing gastric acid.
Purity & Quality Control
Choose Selective Proton Pump Inhibitors
|Description||Lansoprazole is a proton-pump inhibitor (PPI) which prevents the stomach from producing gastric acid.|
Lansoprazole inhibits gastric acid secretion via inhibition of gastric hydrogen/potassium adenosine triphosphatase (H+,K(+)-ATPase), an enzyme of the gastric parietal cell membrane that forms part of the proton pump that performs the final step in the acid secretory process. Lansoprazole binds covalently to parietal cell H+,K(+)-ATPase, rendering it nonfunctional and inhibiting the secretion of gastric acid.  Lansoprazole is a strong anti-secretory agent that acts on gastric H+/K+-adenosine triphosphatase (H+/K+ ATPase) of parietal cells. Lansoprazole inhibits the increased expression of vascular adhesion molecules, the activation of neutrophils, and the production of pro-inflammatory cytokines from activated endothelial cells. Lansoprazole induces several genes, including phase II detoxifying enzyme (NADPH-ubiquinone oxidoreductase, glutathione S-transferase) and antioxidant stress proteins (HO-1, thioredoxin reductase, and superoxide dismutase) in gastric epithelial cells. Lansoprazole significantly inhibits the production of CINC-1 from stimulated RGM-1 cells with IL-1β. Lansoprazole up-regulates HO-1 expression throughout Nrf2 in rat gastric epithelial cells, and the up-regulated HO-1 has anti-inflammatory effects. 
|In vivo||Lansoprazole inhibits acute inflammatory reactions as well as intestinal mucosal injuries induced by ischemia-reperfusion or indomethacin administration in rats. Lansoprazole significantly inhibits intestinal injuries induced by ischemia-reperfusion or indomethacin. lansoprazole administered exogenously prevents the small intestine against ischemia-reperfusion or indomethacin-induced damage, the action being dependent on its anti-inflammatory and anti-oxidative responses. |
|In vitro||DMSO||74 mg/mL (200.34 mM)|
|Ethanol||14 mg/mL (37.9 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT03050307||Not yet recruiting||Gastric Ulcer|Peptic Ulcer|Gastrointestinal Diseases|Digestive System Diseases|Lansoprazole|Anti-Ulcer Agents|Gastrointestinal Agents|Proton Pump Inhibitors|Enzyme Inhibitors|Molecular Mechanisms of Pharmacological Action||Takeda||April 2017||Phase 3|
|NCT03050359||Not yet recruiting||Duodenal Ulcer||Takeda||April 2017||Phase 3|
|NCT03015610||Not yet recruiting||Asthma|Gastroesophageal Reflux||Jason Lang, M.D., M.P.H.|Thrasher Research Fund|Nemours Childrens Clinic|Duke University||January 2017||Phase 3|
|NCT03011125||Not yet recruiting||Safety Issues||First Affiliated Hospital of Zhejiang University|Jiangsu Aosaikang Oharmaceutical Co. Ltd||January 2017||Phase 1|
|NCT02873689||Recruiting||Heartburn|Gastroesophageal Reflux Disease||Takeda||December 2016||Phase 3|
|NCT02873702||Recruiting||Erosive Esophagitis||Takeda||December 2016||Phase 3|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.